# Anti-Inflammatory Effects of Sesamin-Loaded Nanoparticles in LPS-Stimulated RAW 264.7 Macrophages

**Authors:** Kantamanee Jantadee, Kantaporn Kheawfu, Supachoke Mangmool, Takron Chantadee, Siriporn Okonogi, Chuda Chittasupho

PMC · DOI: 10.3390/pharmaceutics18020226 · 2026-02-10

## TL;DR

This study shows that loading sesamin into nanoparticles improves its anti-inflammatory effects in macrophages, making it a better candidate for therapeutic use.

## Contribution

The development of phosphatidylcholine-based nanoparticles to enhance sesamin's solubility and anti-inflammatory efficacy.

## Key findings

- NSM nanoparticles showed significantly better NO inhibition compared to pure sesamin in LPS-stimulated macrophages.
- NSM effectively suppressed the secretion of PGE2, TNF-α, IL-1β, and IL-6 in a dose-dependent manner.
- NSM demonstrated rapid and complete in vitro release of sesamin within 2 hours, unlike pure sesamin.

## Abstract

Background/Objectives: Sesamin is a bioactive lignan with well-documented anti-inflammatory activity but limited therapeutic application due to poor aqueous solubility and low bioavailability. This study developed phosphatidylcholine-based sesamin-loaded nanoparticles (NSM) to enhance sesamin dispersibility, stability, and anti-inflammatory efficacy. Methods: NSM were prepared by solvent displacement. In vitro release was evaluated. Cytotoxicity testing in RAW 264.7 macrophages identified non-toxic concentration ranges for subsequent assays. Anti-inflammatory activity was assessed in lipopolysaccharide (LPS)-stimulated macrophages. Results: NSM exhibited a hydrodynamic diameter of 113.6 ± 3.6 nm with an acceptable PDI, remaining physically and chemically stable for 90 days at 4 °C. In vitro release revealed rapid and complete sesamin liberation from NSM within 2 h, whereas pure sesamin showed negligible release due to poor solubility. In LPS-stimulated macrophages, NSM significantly enhanced nitric oxide (NO) inhibition with an IC50 of 4.92 ± 0.40 µg/mL, markedly lower than sesamin (21.11 ± 3.42 µg/mL) and blank nanoparticles. NSM also strongly suppressed LPS-induced secretion of PGE2, TNF-α, IL-1β, and IL-6 in a dose-dependent manner, demonstrating superior inhibitory effects compared with pure sesamin. Conclusions: These findings indicate that phosphatidylcholine-based nanoparticles substantially enhance the anti-inflammatory potency of sesamin by increasing its solubility, cellular uptake, and biological activity. NSM represents a promising delivery platform for natural anti-inflammatory agents and warrants further investigation for therapeutic applications.

## Linked entities

- **Chemicals:** Sesamin (PubChem CID 5204), Nitric oxide (PubChem CID 145068), PGE2 (PubChem CID 5280360), IL-6 (PubChem CID 165368475)

## Full-text entities

- **Genes:** Mrc1 (mannose receptor, C type 1) [NCBI Gene 17533] {aka CD206, MR}, COX2 (cytochrome c oxidase subunit II) [NCBI Gene 17709], Nfkbia (nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha) [NCBI Gene 18035] {aka Nfkbi}, Il6 (interleukin 6) [NCBI Gene 16193] {aka Il-6}, Mapk8 (mitogen-activated protein kinase 8) [NCBI Gene 26419] {aka JNK, JNK1, Prkm8, SAPK1}, Nfkb1 (nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105) [NCBI Gene 18033] {aka NF-KB1, NF-kappaB, NF-kappaB1, p105, p50, p50/p105}, Mapk14 (mitogen-activated protein kinase 14) [NCBI Gene 26416] {aka CSBP2, Crk1, Csbp1, Mxi2, PRKM14, PRKM15}, Cd86 (CD86 antigen) [NCBI Gene 12524] {aka B7, B7-2, B7.2, B70, CLS1, Cd28l2}, Il1b (interleukin 1 beta) [NCBI Gene 16176] {aka IL-1beta, Il-1b}, Tax1bp1 (Tax1 (human T cell leukemia virus type I) binding protein 1) [NCBI Gene 52440] {aka 1200003J11Rik, 1700069J21Rik, D6Ertd404e, D6Ertd772e, T6bp, TXBP151}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, Tlr4 (toll-like receptor 4) [NCBI Gene 21898] {aka Lps, Ly87, Ran/M1, Rasl2-8}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, Ptgs2 (prostaglandin-endoperoxide synthase 2) [NCBI Gene 19225] {aka COX2, Cox-2, PES-2, PGHS-2, PHS II, PHS-2}, Cxcl15 (C-X-C motif chemokine ligand 15) [NCBI Gene 20309] {aka Il8, Scyb15, lungkine, weche}, Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, Tnfaip3 (tumor necrosis factor, alpha-induced protein 3) [NCBI Gene 21929] {aka A20, Tnfip3}, Nos2 (nitric oxide synthase 2, inducible) [NCBI Gene 18126] {aka MAC-NOS, NOS-II, Nos-2, Nos2a, i-NOS, iNOS}
- **Diseases:** Inflammation (MESH:D007249), injury to (MESH:D014947), Inflammatory Cytokines (MESH:D000080424), tissue injury (MESH:D017695), chronic disease (MESH:D002908), infection (MESH:D007239), Cytotoxicity (MESH:D064420)
- **Chemicals:** water (MESH:D014867), benzene (MESH:D001554), phospholipid (MESH:D010743), PGE2 (MESH:D015232), PEG 400 (MESH:C000595213), N-(1-naphthyl) ethylenediamine (MESH:C008588), copper (MESH:D003300), NO (MESH:D009569), BAY 11-7083 (MESH:C416282), Sesamin (MESH:C054125), Methanol (MESH:D000432), formazan (MESH:D005562), polymers (MESH:D011108), streptomycin (MESH:D013307), carbon (MESH:D002244), CO2 (MESH:D002245), Lipid (MESH:D008055), LPS (MESH:D008070), DMSO (MESH:D004121), lecithin (MESH:D054709), NPs (MESH:D009405), Dulbecco's Modified Eagle Medium (-), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MESH:C022616), Poloxamer 407 (MESH:D020442), Sulfanilamide (MESH:D000077145), penicillin (MESH:D010406), lignan (MESH:D017705), Indomethacin (MESH:D007213), Nitrite (MESH:D009573), MTT (MESH:C070243), phosphoric acid (MESH:C030242), phosphotungstic acid (MESH:D010772), fatty acid (MESH:D005227), acetone (MESH:D000096), PC (MESH:D010713)
- **Species:** Escherichia coli O111:B4 (no rank) [taxon 1090940], Sesamum indicum (beniseed, species) [taxon 4182], Rattus norvegicus (brown rat, species) [taxon 10116], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** RAW 264.7 — Mus musculus (Mouse), Mouse leukemia, Cancer cell line (CVCL_0493), MG6 — Mus musculus (Mouse), Transformed cell line (CVCL_8732), BV-2 — Mus musculus (Mouse), Transformed cell line (CVCL_0182), J774.1 — Mus musculus (Mouse), Mouse reticulum cell sarcoma, Cancer cell line (CVCL_0358)

## Figures

11 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12944416/full.md

---
Source: https://tomesphere.com/paper/PMC12944416